Lineage Cell Therapeutics Inc (AMEX:LCTX) At $1.09: What To Do?

In recent trading session, Lineage Cell Therapeutics Inc (AMEX:LCTX) saw 0.72 million shares changing hands at last check today with its beta currently measuring 1.27. Company’s recent per share price level of $1.09 trading at $0.01 or 0.93% at last check today assigns it a market valuation of $190.74M. That most recent trading price of LCTX’s stock is at a discount of -44.04% from its 52-week high price of $1.57 and is indicating a premium of 22.94% from its 52-week low price of $0.84. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.92 million shares which gives us an average trading volume of 732.46K if we extend that period to 3-months.

Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information

Upright in the green today for gaining 0.93%, in the last five days LCTX remained trading in the green while hitting it’s week-highest on Tuesday, 02/06/24 when the stock touched $1.09 price level, adding 5.22% to its value on the day. Lineage Cell Therapeutics Inc’s shares saw a change of 0.00% in year-to-date performance and have moved 11.22% in past 5-day. Lineage Cell Therapeutics Inc (AMEX:LCTX) showed a performance of -9.17% in past 30-days. Number of shares sold short was 7.88 million shares which calculate 8.16 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts

Statistics highlight that Lineage Cell Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -22.70% of value to its shares in past 6 months, showing an annual growth rate of 6.67% while that of industry is 15.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.87% during past 5 years.

LCTX Dividends

Lineage Cell Therapeutics Inc is more likely to be releasing its next quarterly report between March 07 and March 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders

Insiders are in possession of 3.99% of company’s total shares while institution are holding 40.21 percent of that, with stock having share float percentage of 41.88%. Investors also watch the number of corporate investors in a company very closely, which is 40.21% institutions for Lineage Cell Therapeutics Inc that are currently holding shares of the company. Broadwood Capital, Inc. is the top institutional holder at LCTX for having 34.94 million shares of worth $49.26 million. And as of Jun 29, 2023, it was holding 19.96% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 9.01 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 5.15% of outstanding shares, having a total worth of $12.71 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 4.52 million shares of worth $6.38 million or 2.59% of the total outstanding shares. The later fund manager was in possession of 2.54 million shares on Aug 30, 2023, making its stake of worth around $3.35 million in the company or a holder of 1.45% of company’s stock.

On Key

Related Posts